{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:08:11Z","timestamp":1793372891608,"version":"4.5.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s40265-018-0956-9","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T08:48:21Z","timestamp":1533113301000},"page":"1187-1195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Adult-Onset Still\u2019s Disease: Molecular Pathophysiology and Therapeutic Advances"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6432-7174","authenticated-orcid":false,"given":"Paolo","family":"Sfriso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bindoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Galozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,1]]},"reference":[{"key":"956_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/07853890.2014.971052","volume":"47","author":"S Kadavath","year":"2015","unstructured":"Kadavath S, Efthimiou P. Adult-onset Still\u2019s disease-pathogenesis, clinical manifestations, and new treatment options. Ann Med. 2015;47:6\u201314.","journal-title":"Ann Med"},{"key":"956_CR2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s10067-016-3308-8","volume":"35","author":"P Sfriso","year":"2016","unstructured":"Sfriso P, Priori R, Valesini G, Rossi S, Montecucco CM, D\u2019Ascanio A, et al. Adult-onset Still\u2019s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol. 2016;35:1683\u20139.","journal-title":"Clin Rheumatol"},{"key":"956_CR3","first-page":"424","volume":"19","author":"M Yamaguchi","year":"1992","unstructured":"Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still\u2019s disease. J Rheumatol. 1992;19:424\u201330.","journal-title":"J Rheumatol"},{"key":"956_CR4","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.autrev.2014.08.032","volume":"13","author":"AT Maria","year":"2014","unstructured":"Maria AT, Le Quellec A, Jorgensen C, Touitou I, Rivi\u00e8re S, Guilpain P. Adult onset Still\u2019s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev. 2014;13:1149\u201359.","journal-title":"Autoimmun Rev"},{"key":"956_CR5","unstructured":"Pouchot J, Fautrel B. Maladie de Still de l\u2019adulte. In: Piette JC, Meyer O, Sibilia J, editors. M\u00e9decine\/Sciences F. Maladies et syndromes syst\u00e9miques, 5\u00e8me \u00e9dition Paris: M\u00e9decine Sciences Flammarion; 2008; vol. 1. p. 449\u201368."},{"key":"956_CR6","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1093\/rheumatology\/40.12.1398","volume":"40","author":"T Fujii","year":"2001","unstructured":"Fujii T, Nojima T, Yasuoka H, Satoh S, Nakamura K, Kuwana M, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still\u2019s disease. Assoc Chron Articul Dis Rheumatol (Oxford). 2001;40:1398\u2013404.","journal-title":"Assoc Chron Articul Dis Rheumatol (Oxford)"},{"key":"956_CR7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/ard.54.7.587","volume":"54","author":"G Magadur-Joly","year":"1995","unstructured":"Magadur-Joly G, Billaud E, Barrier JH, Pennec YL, Masson C, Renou P, et al. Epidemiology of adult Still\u2019s disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis. 1995;54:587\u201390.","journal-title":"Ann Rheum Dis"},{"key":"956_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2188\/jea.7.221","volume":"7","author":"K Wakai","year":"1997","unstructured":"Wakai K, Ohta A, Tamakoshi A, Ohno Y, Kawamura T, Aoki R, et al. Estimated prevalence and incidence of adult Still\u2019s disease: findings by a nationwide epidemiological survey in Japan. J Epidemiol. 1997;7:221\u20135.","journal-title":"J Epidemiol"},{"key":"956_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/03009740510026616","volume":"35","author":"KJ Evensen","year":"2006","unstructured":"Evensen KJ, Nossent HC. Epidemiology and outcome of adult-onset Still\u2019s disease in Northern Norway. Scand J Rheumatol. 2006;35:48\u201351.","journal-title":"Scand J Rheumatol"},{"key":"956_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12026-014-8561-9","volume":"61","author":"Y Jamilloux","year":"2015","unstructured":"Jamilloux Y, Gerfaud-Valentin M, Martinon F, Belot A, Henry T, Seve P. Pathogenesis of adult-onset Still\u2019s disease: new insights from the juvenile counterpart. Immunol Res. 2015;61:53\u201362.","journal-title":"Immunol Res"},{"key":"956_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12969-015-0047-3","volume":"13","author":"N Nirmala","year":"2015","unstructured":"Nirmala N, Brachat A, Feist E, Blank N, Specker C, Witt M, et al. Gene-expression analysis of adult-onset Still\u2019s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J. 2015;13:50.","journal-title":"Pediatr Rheumatol Online J."},{"key":"956_CR12","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S0002-9343(99)80318-0","volume":"98","author":"JS Sampalis","year":"1995","unstructured":"Sampalis JS, Esdaile JM, Medsger TA, Partridge AJ, Yeadon C, Sen\u00e9cal JL, et al. A controlled study of the long-term prognosis of adult Still\u2019s disease. Am J Med. 1995;98:384\u20138.","journal-title":"Am J Med"},{"key":"956_CR13","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1002\/art.1780241203","volume":"12","author":"R Terkeltaub","year":"1981","unstructured":"Terkeltaub R, Esdaile J, D\u00e9cary F, Harth M, Lister J, Lapointe N. HLA-Bw35 and prognosis in adult Still\u2019s disease. Arthritis Rheum. 1981;12:1469\u201372.","journal-title":"Arthritis Rheum"},{"key":"956_CR14","first-page":"489","volume":"21","author":"CI Joung","year":"2003","unstructured":"Joung CI, Lee HS, Lee SW, Kim CG, Song YH, Jun JB, et al. Association between HLA-DR B1 and clinical features of adult onset Still\u2019s disease in Korea. Clin Exp Rheumatol. 2003;21:489\u201392.","journal-title":"Clin Exp Rheumatol"},{"key":"956_CR15","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/sj.gene.6363922","volume":"3","author":"T Sugiura","year":"2002","unstructured":"Sugiura T, Kawaguchi Y, Harigai M, Terajima-Ichida H, Kitamura Y, Furuya T, et al. Association between adult-onset Still\u2019s disease and interleukin-18 gene polymorphisms. Genes Immun. 2002;3:394\u20139.","journal-title":"Genes Immun"},{"key":"956_CR16","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1186\/ar4239","volume":"15","author":"FF Wang","year":"2013","unstructured":"Wang FF, Huang XF, Shen N, Leng L, Bucala R, Chen SL, et al. A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still\u2019s disease. Arthritis Res Ther. 2013;15:R65.","journal-title":"Arthritis Res Ther."},{"key":"956_CR17","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1172\/JCI2629","volume":"102","author":"D Fishman","year":"1998","unstructured":"Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102:1369\u201376.","journal-title":"J Clin Invest"},{"key":"956_CR18","doi-asserted-by":"crossref","unstructured":"Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58:1505\u201315.","DOI":"10.1002\/art.23437"},{"key":"956_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00296-017-3885-0","volume":"38","author":"R Sighart","year":"2018","unstructured":"Sighart R, Rech J, Hueber A, Blank N, L\u00f6hr S, Reis A, et al. Evidence for genetic overlap between adult onset Still\u2019s disease and hereditary periodic fever syndromes. Rheumatol Int. 2018;38:111\u201320.","journal-title":"Rheumatol Int"},{"key":"956_CR20","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1136\/ard.47.9.764","volume":"47","author":"JM Wouters","year":"1988","unstructured":"Wouters JM, van der Veen J, van de Putte LB, de Rooij DJ. Adult onset Still\u2019s disease and viral infections. Ann Rheum Dis. 1988;47:764\u20137.","journal-title":"Ann Rheum Dis"},{"key":"956_CR21","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/BF02208701","volume":"10","author":"E Balleari","year":"1991","unstructured":"Balleari E, Cutolo M, Accardo S. Adult-onset Still\u2019s disease associated to toxoplasma gondii infection. Clin Rheumatol. 1991;10:326\u20137.","journal-title":"Clin Rheumatol"},{"key":"956_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.revmed.2013.02.014","volume":"35","author":"E Liozon","year":"2014","unstructured":"Liozon E, Ly KH, Vidal-Cathala E, Fauchais AL. Adult-onset Still\u2019s disease as a manifestation of malignancy: report of a patient with melanoma and literature review. Rev Med Interne. 2014;35:60\u20134.","journal-title":"Rev Med Interne"},{"key":"956_CR23","doi-asserted-by":"publisher","first-page":"R39","DOI":"10.1186\/ar4193","volume":"15","author":"DY Chen","year":"2013","unstructured":"Chen DY, Lin CC, Chen YM, Lan JL, Hung WT, Chen HH, et al. Involvement of TLR7 MyD88-dependent signaling pathway in the pathogenesis of adult-onset Still\u2019s disease. Arthritis Res Ther. 2013;15:R39.","journal-title":"Arthritis Res Ther"},{"key":"956_CR24","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","volume":"13","author":"M Gerfaud-Valentin","year":"2014","unstructured":"Gerfaud-Valentin M, Jamilloux Y, Iwaz J, S\u00e8ve P. Adult-onset Still\u2019s disease. Autoimmun Rev. 2014;13:708\u201322.","journal-title":"Autoimmun Rev"},{"key":"956_CR25","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3109\/03009742.2011.644325","volume":"41","author":"A Komiya","year":"2012","unstructured":"Komiya A, Matsui T, Nogi S, Iwata K, Futami H, Takaoka H, et al. Neutrophil CD64 is upregulated in patients with active adult-onset Still\u2019s disease. Scand J Rheumatol. 2012;41:156\u20138.","journal-title":"Scand J Rheumatol"},{"key":"956_CR26","first-page":"2422","volume":"30","author":"JH Choi","year":"2003","unstructured":"Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, et al. Serum cytokine profiles in patients with adult onset Still\u2019s disease. J Rheumatol. 2003;30:2422\u20137.","journal-title":"J Rheumatol"},{"key":"956_CR27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/rheumatology\/38.5.477","volume":"38","author":"K Matsui","year":"1999","unstructured":"Matsui K, Tsuchida T, Hiroishi K, Tominaga K, Hayashi N, Hada T, et al. High serum level of macrophage-colony stimulating factor (M-CSF) in adult-onset Still\u2019s disease. Rheumatology (Oxford). 1999;38:477\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"956_CR28","first-page":"396","volume":"25","author":"T Hoshino","year":"1998","unstructured":"Hoshino T, Ohta A, Yang D, Kawamoto M, Kikuchi M, Inoue Y, et al. Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still\u2019s disease. J Rheumatol. 1998;25:396\u20138.","journal-title":"J Rheumatol"},{"key":"956_CR29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.clinbiochem.2008.01.008","volume":"41","author":"YQ Zou","year":"2008","unstructured":"Zou YQ, Lu LJ, Li SJ, Zeng T, Wang XD, Bao CD, et al. The levels of macrophage migration inhibitory factor as an indicator of disease activity and severity in adult-onset Still\u2019s disease. Clin Biochem. 2008;41:519\u201324.","journal-title":"Clin Biochem"},{"key":"956_CR30","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/art.21164","volume":"53","author":"DY Chen","year":"2005","unstructured":"Chen DY, Lan JL, Lin FJ, Hsieh TY. Association of intercellular adhesion molecule-1 with clinical manifestations and interleukin-18 in patients with active, untreated adult-onset Still\u2019s disease. Arthritis Rheum. 2005;53:320\u20137.","journal-title":"Arthritis Rheum"},{"key":"956_CR31","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1002\/art.34514","volume":"64","author":"SJ Lee","year":"2012","unstructured":"Lee SJ, Cho YN, Kim TJ, Park SC, Park DJ, Jin HM, et al. Natural killer T cell deficiency in active adult-onset Still\u2019s Disease: correlation of deficiency of natural killer T cells with dysfunction of natural killer cells. Arthritis Rheum. 2012;64:2868\u201377.","journal-title":"Arthritis Rheum"},{"key":"956_CR32","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/rheumatology\/keg074","volume":"42","author":"NM Wulffraat","year":"2003","unstructured":"Wulffraat NM, Rijkers GT, Elst E, Brooimans R, Kuis W. Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford). 2003;42:375\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"956_CR33","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1182\/blood-2008-03-146720","volume":"113","author":"MG Netea","year":"2009","unstructured":"Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood. 2009;113:2324\u201335.","journal-title":"Blood"},{"key":"956_CR34","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3899\/jrheum.161354","volume":"44","author":"CW Hsieh","year":"2017","unstructured":"Hsieh CW, Chen YM, Lin CC, Tang KT, Chen HH, Hung WT, et al. Elevated expression of the NLRP3 inflammasome and its correlation with disease activity in adult-onset still disease. J Rheumatol. 2017;44:1142\u201350.","journal-title":"J Rheumatol"},{"key":"956_CR35","first-page":"3364","volume":"17","author":"DY Chen","year":"2018","unstructured":"Chen DY, Chen YM, Chen HH, Hsieh CW, Gung NR, Hung WT, et al. Human parvovirus B19 nonstructural protein NS1 activates NLRP3 inflammasome signaling in adult-onset Still\u2019s disease. Mol Med Rep. 2018;17:3364\u201371.","journal-title":"Mol Med Rep."},{"key":"956_CR36","doi-asserted-by":"publisher","first-page":"981232","DOI":"10.1155\/2013\/981232","volume":"2013","author":"KM Antoniou","year":"2013","unstructured":"Antoniou KM, Margaritopoulos GA, Giannarakis I, Choulaki C, Fountoulakis N, Siafakas NM, et al. Adult onset Still\u2019s disease: a case report with a rare clinical manifestation and pathophysiological correlations. Case Rep Med. 2013;2013:981232.","journal-title":"Case Rep Med"},{"key":"956_CR37","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1136\/ard.2003.013680","volume":"63","author":"DY Chen","year":"2004","unstructured":"Chen DY, Lan JL, Lin FJ, Hsieh TY, Wen MC. Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still\u2019s disease. Ann Rheum Dis. 2004;63:1300\u20136.","journal-title":"Ann Rheum Dis"},{"key":"956_CR38","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3109\/03008200903461462","volume":"51","author":"DY Chen","year":"2010","unstructured":"Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL. The associations of circulating CD4+CD25 high regulatory T cells and TGF- b with disease activity and clinical course in patients with adult-onset Still\u2019s disease. Connect Tissue Res. 2010;51:370\u20137.","journal-title":"Connect Tissue Res"},{"key":"956_CR39","first-page":"2189","volume":"31","author":"DY Chen","year":"2004","unstructured":"Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still\u2019s disease. J Rheumatol. 2004;31:2189\u201398.","journal-title":"J Rheumatol"},{"key":"956_CR40","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.cell.2010.03.002","volume":"140","author":"DL Kastner","year":"2010","unstructured":"Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell. 2010;140:784\u201390.","journal-title":"Cell"},{"key":"956_CR41","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1136\/ard.2003.016428","volume":"63","author":"T Rooney","year":"2004","unstructured":"Rooney T, Murphy E, Benito M, Roux-Lombard P, FitzGerald O, Dayer J-M, et al. Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Ann Rheum Dis. 2004;63:1393\u20138.","journal-title":"Ann Rheum Dis"},{"key":"956_CR42","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1093\/rheumatology\/keq397","volume":"50","author":"R Priori","year":"2011","unstructured":"Priori R, Barone F, Alessandri C, Colafrancesco S, McInnes IB, Pitzalis C, et al. Markedly increased IL-18 liver expression in adult-onset Still\u2019s disease-related hepatitis. Rheumatology (Oxford). 2011;50:776\u201380.","journal-title":"Rheumatology (Oxford)"},{"key":"956_CR43","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5","volume":"44","author":"M Kawashima","year":"2001","unstructured":"Kawashima M, Yamamura M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still\u2019s disease. Arthritis Rheum. 2001;44:550\u201360.","journal-title":"Arthritis Rheum"},{"key":"956_CR44","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3899\/jrheum.090662","volume":"37","author":"J Maruyama","year":"2010","unstructured":"Maruyama J, Inokuma S. Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol. 2010;37:967\u201373.","journal-title":"J Rheumatol"},{"key":"956_CR45","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","volume":"77","author":"C Gabay","year":"2018","unstructured":"Gabay C, Fautrel B, Rech J, Spertini F, Feist E, K\u00f6tter I, et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease. Ann Rheum Dis. 2018;77:840\u20137.","journal-title":"Ann Rheum Dis"},{"key":"956_CR46","first-page":"653","volume":"14","author":"MA Scheinberg","year":"1996","unstructured":"Scheinberg MA, Chapira E, Fernandes ML, Hubscher O. Interleukin 6: a possible marker of disease activity in adult onset Still\u2019s disease. Clin Exp Rheumatol. 1996;14:653\u20135.","journal-title":"Clin Exp Rheumatol"},{"key":"956_CR47","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1093\/rheumatology\/keq284","volume":"49","author":"DY Chen","year":"2010","unstructured":"Chen DY, Chen YM, Lan JL, Lin CC, Chen HH, Hsieh CW. Potential role of Th17 cells in the pathogenesis of adult-onset Still\u2019s disease. Rheumatology (Oxford). 2010;49:2305\u201312.","journal-title":"Rheumatology (Oxford)"},{"key":"956_CR48","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1182\/blood-2004-08-2997","volume":"105","author":"AD Billiau","year":"2005","unstructured":"Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood. 2005;105:1648\u201351.","journal-title":"Blood"},{"key":"956_CR49","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/art.38362","volume":"66","author":"SW Canna","year":"2014","unstructured":"Canna SW. Interferon-\u03b3: friend or foe in systemic juvenile idiopathic arthritis and adult Still\u2019s Disease. Arthritis Rheumatol. 2014;66:1072\u20136.","journal-title":"Arthritis Rheumatol."},{"key":"956_CR50","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1002\/art.38359","volume":"66","author":"A Avau","year":"2014","unstructured":"Avau A, Mitera T, Put S, Put K, Brisse E, Filtjens J, et al. Systemic juvenile idiopathic arthritis-like syndrome in mice following stimulation of the immune system with Freund\u2019s complete adjuvant: regulation by interferon-\u03b3. Arthritis Rheumatol. 2014;66:1340\u201351.","journal-title":"Arthritis Rheumatol."},{"key":"956_CR51","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s10067-012-1952-1","volume":"31","author":"T Kasama","year":"2012","unstructured":"Kasama T, Furuya H, Yanai R, Ohtsuka K, Takahashi R, Yajima N, et al. Correlation of serum CX3CL1 level with disease activity in adult-onset Still\u2019s disease and significant involvement in hemophagocytic syndrome. Clin Rheumatol. 2012;31:853\u201360.","journal-title":"Clin Rheumatol"},{"key":"956_CR52","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.autrev.2017.07.017","volume":"16","author":"M Govoni","year":"2017","unstructured":"Govoni M, Bortoluzzi A, Rossi D, Modena V. How I treat patients with adult onset Still\u2019s disease in clinical practice. Autoimmun Rev. 2017;16:1016\u201323.","journal-title":"Autoimmun Rev"},{"key":"956_CR53","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1002\/art.27532","volume":"62","author":"S Franchini","year":"2010","unstructured":"Franchini S, Dagna L, Salvo F, Aiello P, Baldissera E, Sabbadini MG. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still\u2019s disease. Arthritis Rheum. 2010;62:2530\u20135.","journal-title":"Arthritis Rheum"},{"key":"956_CR54","first-page":"1055","volume":"61","author":"JM Wouters","year":"1986","unstructured":"Wouters JM, van de Putte LB. Adult-onset Still\u2019s disease; clinical and laboratory features, treatment and progress of 45 cases. QJM. 1986;61:1055\u201365.","journal-title":"QJM"},{"key":"956_CR55","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MD.0000000000000021","volume":"93","author":"M Gerfaud-Valentin","year":"2014","unstructured":"Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, et al. Adult-onset Still disease: manifestations, treatments, outcome, and prognostic factors in 57 patients. Medicine (Baltimore). 2014;93:91\u20139.","journal-title":"Medicine (Baltimore)"},{"key":"956_CR56","first-page":"28","volume":"32","author":"YJ Kim","year":"2014","unstructured":"Kim YJ, Koo BS, Kim YG, Lee CK, Yoo B. Clinical features and prognosis in 82 patients with adult-onset Still\u2019s disease. Clin Exp Rheumatol. 2014;32:28\u201333.","journal-title":"Clin Exp Rheumatol"},{"key":"956_CR57","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","volume":"70","author":"J Pouchot","year":"1991","unstructured":"Pouchot J, Sampalis JS, Beaudet F, Carette S, Decary F, Salusinsky-Sternbach M, et al. Adult Still\u2019s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70:118\u201336.","journal-title":"Medicine (Baltimore)"},{"key":"956_CR58","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fphar.2017.00369","volume":"8","author":"S Colafrancesco","year":"2017","unstructured":"Colafrancesco S, Priori R, Valesini G, Argolini L, Baldissera E, Bartoloni E, et al. Response to interleukin-1 inhibitors in 140 italian patients with adult-onset still\u2019s disease: a multicentre retrospective observational study. Front Pharmacol. 2017;8:369.","journal-title":"Front Pharmacol."},{"key":"956_CR59","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/rheumatology\/ket250","volume":"53","author":"IA Al-Homood","year":"2014","unstructured":"Al-Homood IA. Biologic treatments for adult-onset Still\u2019s disease. Rheumatology (Oxford). 2014;53:32\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"956_CR60","first-page":"329","volume":"19","author":"L Cavagna","year":"2001","unstructured":"Cavagna L, Caporali R, Epis O, Bobbio-Pallavicini F, Montecucco C. Infliximab in the treatment of adult Still\u2019s disease refractory to conventional therapy. Clin Exp Rheumatol. 2001;19:329\u201332.","journal-title":"Clin Exp Rheumatol"},{"key":"956_CR61","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/art.10231","volume":"46","author":"ME Husni","year":"2002","unstructured":"Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese EM, et al. Etanercept in the treatment of adult patients with Still\u2019s disease. Arthritis Rheum. 2002;46:1171\u20136.","journal-title":"Arthritis Rheum"},{"key":"956_CR62","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/ard.2004.024026","volume":"64","author":"B Fautrel","year":"2005","unstructured":"Fautrel B, Sibilia J, Mariette X, Combe B. Tumour necrosis factor alpha blocking agents in refractory adult Still\u2019s disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64:262\u20136.","journal-title":"Ann Rheum Dis"},{"key":"956_CR63","first-page":"733","volume":"23","author":"M Benucci","year":"2005","unstructured":"Benucci M, Li GF, Del Rosso A, Manfredi M. Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still\u2019s disease: the first case report. Clin Exp Rheumatol. 2005;23:733.","journal-title":"Clin Exp Rheumatol"},{"key":"956_CR64","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1136\/ard.2010.129403","volume":"70","author":"J Rech","year":"2011","unstructured":"Rech J, Ronneberger M, Englbrecht M, Finzel S, Katzenbeisser J, Manger K, et al. Successful treatment of adult-onset Still\u2019s disease refractory to TNF and IL-1 blockade by IL-6 receptor blockade. Ann Rheum Dis. 2011;70:390\u20132.","journal-title":"Ann Rheum Dis"},{"key":"956_CR65","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s10067-011-1735-0","volume":"30","author":"NE Aikawa","year":"2011","unstructured":"Aikawa NE, Ribeiro AC, Saad CG, Pereira RM, Levy M, Silva CA, et al. Is anti-TNF switching in refractory Still\u2019s disease safe and effective? Clin Rheumatol. 2011;30:1129\u201334.","journal-title":"Clin Rheumatol"},{"issue":"14","key":"956_CR66","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","volume":"117","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117(14):3720\u201332.","journal-title":"Blood."},{"key":"956_CR67","doi-asserted-by":"publisher","first-page":"e1554","DOI":"10.1097\/MD.0000000000001554","volume":"94","author":"F Ortiz-Sanjan","year":"2015","unstructured":"Ortiz-Sanjan F, Blanco R, Riancho-Zarrabeitia L, Casta\u00f1eda S, Oliv\u00e9 A, Riveros A, et al. Efficacy of anakinra in refractory adult-onset Still\u2019s disease: multicenter study of 41 patients and literature review. Medicine (Baltimore). 2015;94:e1554.","journal-title":"Medicine (Baltimore)"},{"key":"956_CR68","doi-asserted-by":"crossref","unstructured":"Kone-Paut I, Piram M. Targeting interleukin-1 b in CAPS (cryopyrin-associated periodic) syndromes: what did we learn? Autoimmun Rev 2012;12:77e80.","DOI":"10.1016\/j.autrev.2012.07.026"},{"key":"956_CR69","doi-asserted-by":"publisher","first-page":"317820","DOI":"10.1155\/2012\/317820","volume":"2012","author":"C Giampietro","year":"2012","unstructured":"Giampietro C, Fautrel B. Anti-interleukin-1 agents in adult onset still\u2019s disease. Int J Inflam. 2012;2012:317820.","journal-title":"Int J Inflam."},{"key":"956_CR70","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/ard.2007.076034","volume":"67","author":"T Lequerr\u00e9","year":"2008","unstructured":"Lequerr\u00e9 T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67:302\u20138.","journal-title":"Ann Rheum Dis"},{"key":"956_CR71","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/art.30128","volume":"63","author":"PA Nigrovic","year":"2011","unstructured":"Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011;63:545\u201355.","journal-title":"Arthritis Rheum"},{"key":"956_CR72","doi-asserted-by":"publisher","first-page":"R91","DOI":"10.1186\/ar3366","volume":"13","author":"K Laskari","year":"2011","unstructured":"Laskari K, Tzioufas AG, Moutsopoulos HM. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still\u2019s disease: a case-series study. Arthritis Res Ther. 2011;13:R91.","journal-title":"Arthritis Res Ther"},{"key":"956_CR73","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/ard.2006.066381","volume":"66","author":"GD Kalliolias","year":"2007","unstructured":"Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN. Anakinra treatment in patients with adult-onset Still\u2019s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis. 2007;66:842\u20133.","journal-title":"Ann Rheum Dis"},{"key":"956_CR74","first-page":"758","volume":"25","author":"S Guignard","year":"2007","unstructured":"Guignard S, Dien G, Dougados M. Severe systemic inflammatory response syndrome in a patient with adult onset Still\u2019s disease treated with the anti-IL1 drug anakinra: a case report. Clin Exp Rheumatol. 2007;25:758\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"956_CR75","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/art.33342","volume":"64","author":"N Ruperto","year":"2012","unstructured":"Ruperto N, Quartier P, Wulffraat N, Woo P, Ravelli A, Mouy R, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557\u201367.","journal-title":"Arthritis Rheum"},{"key":"956_CR76","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.semarthrit.2012.03.004","volume":"42","author":"A Kontzias","year":"2012","unstructured":"Kontzias A, Efthimiou P. The use of Canakinumab, a novel IL-1 b long-acting inhibitor, in refractory adult-onset Still\u2019s disease. Semin Arthritis Rheum. 2012;42:201\u20135.","journal-title":"Semin Arthritis Rheum"},{"key":"956_CR77","doi-asserted-by":"crossref","unstructured":"Feist E, Quartier P, Fautrel B, Schneider R, Sfriso P, Efthimiou P, et al. Efficacy and safety of canakinumab in patients with Still\u2019s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol. 2018. (Epub ahead of print).","DOI":"10.1136\/annrheumdis-2017-eular.1979"},{"key":"956_CR78","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1136\/annrheumdis-2012-201409","volume":"71","author":"O Petryna","year":"2012","unstructured":"Petryna O, Cush JJ, Efthimiou P. IL-1 trap rilonacept in refractory adult onset Still\u2019s disease. Ann Rheum Dis. 2012;71:2056\u20137.","journal-title":"Ann Rheum Dis"},{"key":"956_CR79","first-page":"1831","volume":"62","author":"C Henderson","year":"2010","unstructured":"Henderson C, Wilson M, Pham TH, Dolan G, Gobbo A, Snyder C, et al. Safety and efficacy of IL-1 trap in resistant adult onset Still\u2019s disease: 24\u00a0month follow-up of open label treatment and biomarkers of response. Arthritis Rheum. 2010;62:1831.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"956_CR80","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1002\/art.38398","volume":"66","author":"F Ortiz-Sanjuan","year":"2014","unstructured":"Ortiz-Sanjuan F, Blanco R, Calvo-Rio V, Narvaez J, Rubio Romero E, Olive A, et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still\u2019s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol. 2014;66(6):1659\u201365.","journal-title":"Arthritis Rheumatol"},{"key":"956_CR81","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10067-013-2381-5","volume":"33","author":"P Cipriani","year":"2014","unstructured":"Cipriani P, Ruscitti P, Carubbi F, Pantano I, Liakouli V, Berardicurti O, et al. Tocilizumab for the treatment of adult-onset Still\u2019s disease: results from a case series. Clin Rheumatol. 2014;33:49\u201355.","journal-title":"Clin Rheumatol"},{"key":"956_CR82","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3899\/jrheum.130881","volume":"41","author":"O Elkayam","year":"2014","unstructured":"Elkayam O, Jiries N, Dranitzki Z, Kivity S, Lidar M, Levy O, et al. Tocilizumab in adult-onset Still\u2019s disease: the Israeli experience. J Rheumatol. 2014;41:244\u20137.","journal-title":"J Rheumatol"},{"key":"956_CR83","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/acr.20319","volume":"63","author":"X Pu\u00e9chal","year":"2011","unstructured":"Pu\u00e9chal X, DeBandt M, Berthelot JM, Breban M, Dubost JJ, Fain O, et al. Tocilizumab in refractory adult Still\u2019s disease. Arthritis Care Res. 2011;63:155\u20139.","journal-title":"Arthritis Care Res"},{"key":"956_CR84","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1056\/NEJMoa1112802","volume":"367","author":"F Benedetti De","year":"2012","unstructured":"De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385\u201395.","journal-title":"N Engl J Med"},{"key":"956_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2017.1416924","volume":"8","author":"Y Ma","year":"2018","unstructured":"Ma Y, Wu M, Zhang X, Xia Q, Yang J, Xu S, et al. Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still\u2019s disease: a meta-analysis. Mod Rheumatol. 2018;8:1\u20139.","journal-title":"Mod Rheumatol"},{"key":"956_CR86","doi-asserted-by":"publisher","first-page":"5656320","DOI":"10.1155\/2016\/5656320","volume":"2016","author":"E Watanabe","year":"2016","unstructured":"Watanabe E, Sugawara H, Yamashita T, Ishii A, Oda A, Terai C. Successful tocilizumab therapy for macrophage activation syndrome associated with adult-onset Still\u2019s disease: a case-based review. Case Rep Med. 2016;2016:5656320.","journal-title":"Case Rep Med"},{"key":"956_CR87","doi-asserted-by":"publisher","first-page":"e7596","DOI":"10.1097\/MD.0000000000007596","volume":"96","author":"A Masui-Ito","year":"2017","unstructured":"Masui-Ito A, Okamoto R, Ikejiri K, Fujimoto M, Tanimura M, Nakamori S, et al. Tocilizumab for uncontrollable systemic inflammatory response syndrome complicating adult-onset Still disease: case report and review of literature. Medicine (Baltimore). 2017;96:e7596.","journal-title":"Medicine (Baltimore)."},{"key":"956_CR88","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1080\/14397595.2016.1221875","volume":"27","author":"Y Tsuchida","year":"2017","unstructured":"Tsuchida Y, Sumitomo S, Shoda H, Kubo K, Fujio K, Yamamoto K. Macrophage activation syndrome associated with tocilizumab treatment in adult-onset Still\u2019s disease. Mod Rheumatol. 2017;27:556\u20137.","journal-title":"Mod Rheumatol"},{"key":"956_CR89","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/0248-8663(96)80703-X","volume":"16","author":"S Permal","year":"1995","unstructured":"Permal S, Wechsler B, Cabane J, Perrot S, Blum L, Imbert JC. Treatment of Still disease in adults with intravenous immunoglobulins. Rev Med Interne. 1995;16:250\u20134.","journal-title":"Rev Med Interne"},{"key":"956_CR90","first-page":"295","volume":"16","author":"S Vignes","year":"1998","unstructured":"Vignes S, Wechsler B, Amoura Z, Papo T, Franc\u00e8s C, Huong DL, et al. Intravenous immunoglobulin in adult Still\u2019s disease refractory to non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 1998;16:295\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"956_CR91","first-page":"797","volume":"23","author":"AM Prieur","year":"1996","unstructured":"Prieur AM. Intravenous immunoglobulins in Still\u2019s disease: still controversial, still unproven. J Rheumatol. 1996;23:797\u2013800.","journal-title":"J Rheumatol"},{"key":"956_CR92","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/RHU.0b013e31822c53ad","volume":"17","author":"RA Ostrowski","year":"2011","unstructured":"Ostrowski RA, Tehrani R, Kadanoff R. Refractory adult-onset still disease successfully treated with abatacept. J Clin Rheumatol. 2011;17:315\u20137.","journal-title":"J Clin Rheumatol"},{"key":"956_CR93","first-page":"265","volume":"28","author":"L Quartuccio","year":"2010","unstructured":"Quartuccio L, Maset M, De Vita S. Efficacy of abatacept in a refractory case of adult-onset Still\u2019s disease. Clin Exp Rheumatol. 2010;28:265\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"956_CR94","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard.2005.047621","volume":"65","author":"K Ahmadi-Simab","year":"2006","unstructured":"Ahmadi-Simab K, Lamprecht P, Jankowiak C, Gross WL. Successful treatment of refractory adult onset Still\u2019s disease with rituximab. Ann Rheum Dis. 2006;65:1117\u20138.","journal-title":"Ann Rheum Dis"},{"key":"956_CR95","first-page":"888","volume":"27","author":"E Bartoloni","year":"2009","unstructured":"Bartoloni E, Alunno A, Luccioli F, Santoboni G, Gerli R. Successful treatment of refractory adult-onset Still\u2019s disease with anti-CD20 monoclonal antibody. Clin Exp Rheumatol. 2009;27:888\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"956_CR96","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/acr.21901","volume":"65","author":"C Giampietro","year":"2013","unstructured":"Giampietro C, Ridene M, Lequerre T, Costedoat Chalumeau N, Amoura Z, Sellam J, et al. Anakinra in adult-onset Still\u2019s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res (Hoboken). 2013;65:822\u20136.","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-0956-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0956-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0956-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T04:22:54Z","timestamp":1751775774000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-0956-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":96,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["956"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0956-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"1 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to conduct this study or prepare this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Paolo Sfriso, Sara Bindoli, and Paola Galozzi have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}